The DOI matches its Crossref record; 281 of the 281 references it cites were found in a registry or an index.
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Abstract
Conventional chemotherapeutics have been developed into clinically useful agents based on their ability to preferentially kill malignant cells, generally owing to their elevated proliferation rate. Nonetheless, the clinical activity of various chemotherapies is now known to involve the stimulation of anticancer immunity either by initiating the release of immunostimulatory molecules from dying cancer cells or by mediating off-target effects on immune cell populations. Understanding the precise immunological mechanisms that underlie the efficacy of chemotherapy has the potential not only to enable the identification of superior biomarkers of response but also to accelerate the development of synergistic combination regimens that enhance the clinical effectiveness of immune checkpoint inhibitors (ICIs) relative to their effectiveness as monotherapies. Indeed, accumulating evidence supports the clinical value of combining appropriately dosed chemotherapies with ICIs. In this Review, we discuss preclinical and clinical data on the immunostimulatory effects of conventional chemotherapeutics in the context of ICI-based immunotherapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Immunogenic cell death is featured with some upregulated damage-associated molecular patterns (DAMPs) such as the secretion of IFN-I, the exposure of endoplasmic reticulum proteins especially calreticulin (CRT, an eat-me signal) on cell membrane, the leak of ATP (a find-me signal), and the release of high-mobility group box 1 (HMGB1) [35].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [35]
Citations
Cites
1 retracted
Items 201–281 of 281
McDonnell, A. M., Lesterhuis, W. J., Khong, A., Nowak, A. K., Lake, R., Currie, A. J., & Robinson, B. W. S. (2014) · European Journal of Immunology · doi:10.1002/eji.201444722 · Cited by 87
Lévesque, S., Le Naour, J., Pietrocola, F., Paillet, J., Kremer, M., Castoldi, F., Baracco, E. E., Wang, Y., Vacchelli, E., Stoll, G., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1657375 · Cited by 86
Self-citationCirone, M., Renzo, L. D., Lotti, L. V., Conte, V., Trivedi, P., Santarelli, R., Gonnella, R., Frati, L., & Faggioni, A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0031732 · Cited by 85
Yeung, J. T., Hamilton, R. L., Ohnishi, K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2861 · Cited by 83
Immunotherapy for the First-Line Treatment of Patients with Metastatic Non–Small Cell Lung Cancer
Martínez, P., Peters, S., Stammers, T. A., & Soria, J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3904 · Cited by 82
Moschella, F., Valentini, M., Aricò, E., Macchia, I., Sestili, P., D’Urso, M. T., Alessandri, C., Belardelli, F., & Proietti, E. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4523 · Cited by 81
Lurbinectedin synergizes with immune checkpoint blockade to generate anticancer immunity
Xie, W., Forveille, S., Iribarren, K., Sauvat, A., Senovilla, L., Wang, Y., Humeau, J., Pérez-Lanzón, M., Zhou, H., Martínez-Leal, J. F., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1656502 · Cited by 81
Self-citationYang, Y., Li, X.-J., Chen, Z., Zhu, X.-X., Wang, J., Zhang, L., Qiang, L., Ma, Y., Li, Z., Guo, Q., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0050811 · Cited by 80
Bauzon, M., Drake, P. M., Barfield, R. M., Cornali, B. M., Rupniewski, I., & Rabuka, D. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1565859 · Cited by 80
Kasikova, L., Hensler, M., Truxova, I., Skapa, P., Laco, J., Belicova, L., Praznovec, I., Vosahlikova, S., Halaska, M. J., Brtnicky, T., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0781-z · Cited by 79
Self-citationEike, L.-M., Yang, N., Rekdal, Ø., & Sveinbjørnsson, B. (2015) · Oncotarget · doi:10.18632/oncotarget.5308 · Cited by 77
Zhou, B., Guo, L., Zhang, B., Liu, S., Zhang, K., Yan, J., Zhang, W., Yu, M., Chen, Z., Xu, Y., et al. (2019) · PubMed Central · Cited by 77
Du, B., & Waxman, D. J. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.11.025 · Cited by 76
D’Eliseo, D., Manzi, L., & Velotti, F. (2013) · Cell Stress and Chaperones · doi:10.1007/s12192-013-0422-2 · Cited by 72
Wesolowski, R., Duggan, M. C., Stiff, A., Markowitz, J., Trikha, P., Levine, K. M., Schoenfield, L., Abdel-Rasoul, M., Layman, R., Ramaswamy, B., et al. (2017) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-017-2038-3 · Cited by 71
Wu, Y., Deng, Z., Wang, H., Ma, W., Zhou, C., & Zhang, S. (2016) · BMC Immunology · doi:10.1186/s12865-016-0167-7 · Cited by 69
Gemcitabine alters the proteasome composition and immunopeptidome of tumour cells
Gravett, A. M., Trautwein, N., Stevanović, S., Dalgleish, A. G., & Copier, J. P. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1438107 · Cited by 68
Select forms of tumor cell apoptosis induce dendritic cell maturation
Demaria, S., Santori, F. R., Ng, B., Liebes, L., Formenti, S. C., & Vukmanović, S. (2004) · Journal of Leukocyte Biology · doi:10.1189/jlb.0804478 · Cited by 67
Treatment of osteosarcoma with microwave thermal ablation to induce immunogenic cell death
Yu, Z., Geng, J., Zhang, M., Zhou, Y., Fan, Q., & Chen, J. (2014) · Oncotarget · doi:10.18632/oncotarget.2310 · Cited by 67
Noblejas‐López, M. D. M., Nieto‐Jiménez, C., Morcillo-García, S., Pérez‐Peña, J., Nuncia‐Cantarero, M., Pretel, F. A., Galán‐Moya, E. M., Amir, E., Pandiella, A., Győrffy, B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1629780 · Cited by 67
Bergmann, C., Bachmann, H. S., Bánkfalvi, Á., Lotfi, R., Pütter, C., Wild, C. A., Schuler, P. J., Greve, J., Hoffmann, T. K., Lang, S., et al. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-139 · Cited by 66
Fukuoka, E., Yamashita, K., Tanaka, T., Sawada, R., Sugita, Y., Arimoto, A., Fujita, M., Takiguchi, G., Matsuda, T., Oshikiri, T., et al. (2019) · Anticancer Research · doi:10.21873/anticanres.13631 · Cited by 66
Myelotoxicity From Chemotherapy
Daniel, D. B., & Crawford, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2005.11.003 · Cited by 64
Camilio, K. A., Rekdal, Ø., & Sveinbjørnsson, B. (2014) · OncoImmunology · doi:10.4161/onci.29181 · Cited by 63
Immunotherapy of Tumors with Neuroimmune Ligand Capsaicin
Beltran, J., Ghosh, A. K., & Basu, S. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.5.3260 · Cited by 63
Relationship Between the Gut Microbiome and Systemic Chemotherapy
Ervin, S. M., Ramanan, S. V., & Bhatt, A. P. (2020) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06119-3 · Cited by 62
Lu, X., Ding, Z., Cao, Y., Liu, C., Habtetsion, T. G., Yu, M., Lemos, H. D. P., Salman, H., Xu, H., Mellor, A. L., et al. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1401894 · Cited by 61
Brusa, D., Garetto, S., Chiorino, G., Scatolini, M., Migliore, E., Camussi, G., & Matera, L. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.08.063 · Cited by 59
Ventura, A., Vassall, A. N., Robinson, E., Filler, R. B., Hanlon, D. J., Meeth, K. M., Ezaldein, H. H., Girardi, M., Sobolev, O., Bosenberg, M., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-18-0171 · Cited by 59
Truxova, I., Kasikova, L., Salek, C., Hensler, M., Lysak, D., Holicek, P., Bilkova, P., Holubova, M., Chen, X., Mikyskova, R., et al. (2020) · Haematologica · doi:10.3324/haematol.2019.223933 · Cited by 56
Self-citationTime-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy
Alagkiozidis, I., Facciabene, A., Tsiatas, M. L., Carpenito, C., Benencia, F., Adams, S. F., Jonak, Z., June, C. H., Powell, D. J., & Coukos, G. (2011) · Journal of Translational Medicine · doi:10.1186/1479-5876-9-77 · Cited by 55
Chen, X., Yang, Y.-A., Zhou, Q., Weiss, J. M., Howard, O. Z., McPherson, J. M., Wakefield, L. M., & Oppenheim, J. J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0085398 · Cited by 55
Martin, S., Dudek-Perić, A. M., Maes, H., Garg, A. D., Gabrysiak, M., Demirsoy, S., Swinnen, J. V., & Agostinis, P. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.12.003 · Cited by 54
Lacour, M., Hiltbrunner, S., Lee, S.-Y., et al. (2019) · Clinical Lung Cancer · doi:10.1016/j.cllc.2019.05.013 · Cited by 54
Riganti, C., Lingua, M. F., Salaroglio, I. C., Falcomatà, C., Righi, L., Morena, D., Picca, F., Oddo, D., Kopecka, J., Pradotto, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398874 · Cited by 53
Sakai, H., Takeda, M., Sakai, K., Nakamura, Y., Ito, A., Hayashi, H., Tanaka, K., Nishio, K., & Nakagawa, K. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.11.025 · Cited by 53
Baseline T cell dysfunction by single cell network profiling in metastatic breast cancer patients
Formenti, S. C., Hawtin, R. E., Dixit, N., Evensen, E., Lee, P., Goldberg, J. D., Li, X., Vanpouille-Box, C., Schaue, D., McBride, W. H., et al. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0633-x · Cited by 53
D’Eliseo, D., Renzo, L. D., Santoni, A., & Velotti, F. (2017) · Genes & Cancer · doi:10.18632/genesandcancer.131 · Cited by 51
Process of immunogenic cell death caused by disulfiram as the anti-colorectal cancer candidate
You, S.-Y., Rui, W., Chen, S.-T., Chen, H.-C., Liu, X., Huang, J., & Chen, H. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.03.192 · Cited by 51
Tremble, L. F., O'Brien, M. A., Soden, D. M., & Forde, P. F. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.11.015 · Cited by 45
Phosphorylated eIF2α predicts disease-free survival in triple-negative breast cancer patients
Guo, L., Chi, Y., Xue, J., et al. (2017) · Scientific Reports · doi:10.1038/srep44674 · Cited by 44
Iida, Y., Harashima, N., Motoshima, T., Komohara, Y., Eto, M., & Harada, M. (2017) · Cancer Science · doi:10.1111/cas.13337 · Cited by 44
CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin
Galaine, J., Turco, C., Vauchy, C., Royer, B., Mercier‐Letondal, P., Queiroz, L., Loyon, R., Mouget, V., Boidot, R., Laheurte, C., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32620 · Cited by 44
Tumor lysis with LTX-401 creates anticancer immunity
Xie, W., Mondragón, L., Mauseth, B., Wang, Y., Pol, J. G., Lévesque, S., Zhou, H., Yamazaki, T., Eksteen, J. J., Zitvogel, L., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1594555 · Cited by 42
Self-citationCapsaicin-mediated apoptosis of human bladder cancer cells activates dendritic cells via CD91
Montani, M. S. G., D’Eliseo, D., Cirone, M., et al. (2014) · Nutrition · doi:10.1016/j.nut.2014.05.005 · Cited by 41
The oncolytic compound LTX-401 targets the Golgi apparatus
Zhou, H., Sauvat, A., Gomes-da-Silva, L. C., Durand, S., Forveille, S., Iribarren, K., Yamazaki, T., Souquère, S., Bezu, L., Müller, K., et al. (2016) · Cell Death and Differentiation · doi:10.1038/cdd.2016.86 · Cited by 41
Self-citationThe key role of calreticulin in immunomodulation induced by chemotherapeutic agents
Yamamura, Y., Tsuchikawa, T., Miyauchi, K., et al. (2014) · International Journal of Clinical Oncology · doi:10.1007/s10147-014-0719-x · Cited by 36
Barbon, C. M., Yang, M., Wands, G. D., Ramesh, R., Slusher, B. S., Hedley, M. L., & Luby, T. M. (2010) · Cellular Immunology · doi:10.1016/j.cellimm.2010.02.007 · Cited by 36
Buccione, C., Fragale, A., Polverino, F., Ziccheddu, G., Aricò, E., Belardelli, F., Proietti, E., Battistini, A., & Moschella, F. (2017) · International Journal of Cancer · doi:10.1002/ijc.31083 · Cited by 36
Sun, C., Wang, H., Mao, S., Ji, L., Li, S., & Wang, J. (2015) · Immunology Letters · doi:10.1016/j.imlet.2015.02.007 · Cited by 34
Beta blockade as adjunctive breast cancer therapy: A review
Phadke, S. D., & Clamon, G. H. (2019) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.04.006 · Cited by 34
Majera, D., Škrott, Z., Bouchal, J., Bártková, J., Šimková, D., Gachechiladze, M. A., Steigerová, J., Kurfürstová, D., Gurský, J., Kořínková, G., et al. (2018) · The Prostate · doi:10.1002/pros.23741 · Cited by 33
Castiello, L., Zevini, A., Vulpis, E., Muscolini, M., Ferrari, M., Palermo, E., Peruzzi, G., Krapp, C., Jakobsen, M. R., Olagnier, D. P., et al. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02380-2 · Cited by 32
Otsubo, D., Yamashita, K., Fujita, M., Nishi, M., Kimura, Y., Hasegawa, H., Suzuki, S., & Kakeji, Y. (2015) · PubMed · Cited by 30
Oncolysis with DTT-205 and DTT-304 generates immunological memory in cured animals
Zhou, H., Mondragón, L., Xie, W., Mauseth, B., Leduc, M., Sauvat, A., Gomes-da-Silva, L. C., Forveille, S., Iribarren, K., Souquère, S., et al. (2018) · Cell Death and Disease · doi:10.1038/s41419-018-1127-3 · Cited by 30
Self-citationSonnemann, J., Greßmann, S., Becker, S., Wittig, S., Schmudde, M., & Beck, J. F. (2010) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-010-1302-4 · Cited by 29
Zhu, X., Xu, J. M., Cai, H., & Lang, J. (2017) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.13521 · Cited by 29
Kokolus, K. M., Haley, J. S., Koubek, E. J., Gowda, R., Dinavahi, S. S., Sharma, A. K., Claxton, D. F., Helm, K. F., Drabick, J. J., Robertson, G. P., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1539614 · Cited by 28
Booth, L. A., Roberts, J. L., Poklepovic, A. S., & Dent, P. (2018) · Cancer Biology & Therapy · doi:10.1080/15384047.2018.1507258 · Cited by 26
Epothilone B enhances Class I HLA and HLA-A2 surface molecule expression in ovarian cancer cells
Pellicciotta, I., Yang, C. H., Goldberg, G. L., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.05.007 · Cited by 24
Urbanová, L., Hradilova, N., Moserova, I. K., Vosahlikova, S., Sadilkova, L. K., Hensler, M., Špíšek, R., & Adkins, I. (2017) · Immunology Letters · doi:10.1016/j.imlet.2017.05.005 · Cited by 24
Markovic, S. N., Suman, V. J., Javed, A., Reid, J. M., Wall, D. J., Erickson, L. A., Ernstoff, M. S., & Anderson, D. M. (2019) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000644 · Cited by 24
Hong, X., Department of General Surgery, Z. H., Dong, T., Yi, T., Hu, J., Zhang, Z., Lin, S., & Niu, W. (2018) · Chinese Journal of Cancer Research · doi:10.21147/j.issn.1000-9604.2018.02.03 · Cited by 23
Mauseth, B., Camilio, K. A., Shi, J., et al. (2019) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2019.05.002 · Cited by 23
BET bromodomain inhibitor JQ1 promotes immunogenic cell death in tongue squamous cell carcinoma
Wang, M., Zhao, L., Tong, D., Yang, L., Zhu, H., Li, Q., & Zhang, F. (2019) · International Immunopharmacology · doi:10.1016/j.intimp.2019.105921 · Cited by 22
Hamy, A., Derosa, L., Valdelièvre, C., Yonekura, S., Opolon, P., Priour, M., Guerin, J., Pierga, J., Asselain, B. J. R., Croze, D. D., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1677427 · Cited by 22
Self-citationImmune induction strategies to enhance responses to PD-1 blockade: lessons from the TONIC trial
Demaria, S., Romano, E., Brackstone, M., & Formenti, S. C. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0783-x · Cited by 20
Bryce, A. H., Dronca, R. S., Costello, B. A., Infante, J. R., Ames, T. D., Jimeno, J. M., & Karp, D. D. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.2020.38.6_suppl.83 · Cited by 20
Eike, L.-M., Mauseth, B., Camilio, K. A., Rekdal, Ø., & Sveinbjørnsson, B. (2016) · PLoS ONE · doi:10.1371/journal.pone.0148980 · Cited by 19
Novel insights into the HLA class I immunopeptidome and T-cell immunosurveillance
Melief, C. J. M., & Kessler, J. H. (2017) · Genome Medicine · doi:10.1186/s13073-017-0439-8 · Cited by 17
Mikyšková, R., Indrová, M., Štěpánek, I., Kanchev, I., Bieblová, J., Vosahlikova, S., Moserova, I. K., Truxová, I., Fucikova, J. P., Bartůňková, J., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1362528 · Cited by 17
Yang, C., He, B., Zheng, Q., Wang, D., Qin, M., Zhang, H., Dai, W., Zhang, Q., Meng, X., & Wang, X. (2019) · Nanomedicine · doi:10.2217/nnm-2019-0074 · Cited by 17
Wang, W., Qin, S., & Zhao, L. (2014) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2014.10.026 · Cited by 16
Nakashima, K., Aoshima, M., Ohfuji, S., Suzuki, K., Katsurada, M., Katsurada, N., Misawa, M., Otsuka, Y., Kondo, K., & Hirota, Y. (2016) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2016.1246094 · Cited by 16
Ghosh, A., Politikos, I., & Perales, M. (2017) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000408 · Cited by 14
Karp, D., Camidge, D. R., Infante, J. R., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy279.424 · Cited by 14
Tongu, M., Harashima, N., Tamada, K., et al. (2014) · Cancer Science · doi:10.1111/cas.12568 · Cited by 12
Fritsch, S., Neumann, S., Schaub, J., Steinbeck, C., & Zielesny, A. (2019) · Journal of Cheminformatics · doi:10.1186/s13321-019-0361-8 · Cited by 12
Unusual nature of long non-coding RNAs coding for “unusual peptides”
Bagchi, A. (2019) · Gene · doi:10.1016/j.gene.2019.144298 · Cited by 5
IPSPs in the slowly adapting stretch receptor of the crayfish.
Jk, J., Ormstad, K., Njå, A., et al. (1970) · PubMed · Cited by 4
[Anthology of urology. Prof. Alexander von Lichtenberg (1880-1980)].
Perez Castro, E. (1981) · PubMed · Cited by 1
Cited by
Sorted by citations
Autophagy in major human diseases
Klionsky, D. J., Petroni, G., Amaravadi, R. K., Baehrecke, E. H., Ballabio, A., Boya, P., Bravo‐San Pedro, J. M., Cadwell, K., Cecconi, F., Choi, A. M. K., et al. (2021) · The EMBO Journal · doi:10.15252/embj.2021108863 · Cited by 1,585
Self-citationCombination strategies with PD-1/PD-L1 blockade: current advances and future directions
Yi, M., Zheng, X., Niu, M., Zhu, S., Ge, H., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-021-01489-2 · Cited by 1,445
Rational combinations of targeted cancer therapies: background, advances and challenges
Jin, H., Wang, L., & Bernards, R. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00615-z · Cited by 503
Optimizing the safety of antibody–drug conjugates for patients with solid tumours
Tarantino, P., Ricciuti, B., Pradhan, S. M., & Tolaney, S. M. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00783-w · Cited by 269
Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms
Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237
Self-citation
Metadata
- Authors
- Galluzzi, L., Humeau, J., Buqué, A., Zitvogel, L., & Kroemer, G.
- Affiliations
- Université Paris Cité (FR)
- Université Paris-Sud (FR)
- Weill Cornell Medicine (US)
- Karolinska University Hospital (SE)
- Corresponding author
- Galluzzi, Lorenzo
- Kroemer, Guido
- Venue
- Nature Reviews Clinical Oncology
- Published
- 2020-08-05
- Volume
- 17
- Issue
- 12
- Pages
- 725-741
- ISSN
- 1759-4774 (ISSN-L)
- 1759-4782
- OpenAlex
- W3047618013
- Cited by
- 1,349
- References
- 281
- Citations by year
- 2026: 150 · 2025: 232 · 2024: 269 · 2023: 282 · 2022: 272 · 2021: 127 · 2020: 17
- FWCI
- 18.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Nature Reviews Clinical Oncology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Agence Nationale de la Recherche (ANR-16-ECVD-0008)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Ferroptosis and cancer prognosis
- Keywords
- chemotherapy, immune checkpoint inhibitors, immunostimulation, cancer immunotherapy, combination therapy, immunogenic cell death, synergy mechanism, treatment response biomarkers
- MeSH terms
- Antineoplastic Agents, Immunological, Immune Checkpoint Inhibitors, Humans, Immunity, Immunization, Immunotherapy, Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
